专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007060028A1 NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS 审中-公开
标题翻译： NAPTHYRIDINE化合物作为岩石抑制剂
公开(公告)号：WO2007060028A1
公开(公告)日：2007-05-31
申请号：PCT/EP2006/050005
申请日：2006-01-02
申请人： GPC BIOTECH AG , MÜLLER, Stefan, , SCHWAB, Wilfried , KLEBL, Bert , HAFENBRADL, Doris , HOPPE, Edmund , HORVATH, Zoltán , KERI, György , VARGA, Zoltán , ÖRFI, László , MAROSFALVI, Jenö , MÜLLER, Gerhard
发明人： MÜLLER, Stefan, , SCHWAB, Wilfried , KLEBL, Bert , HAFENBRADL, Doris , HOPPE, Edmund , HORVATH, Zoltán , KERI, György , VARGA, Zoltán , ÖRFI, László , MAROSFALVI, Jenö , MÜLLER, Gerhard
IPC分类号： C07D471/04 , A61K31/4375 , A61P7/02 , A61P9/00 , A61P11/06 , A61P19/10 , A61P15/10 , A61P27/06 , A61P29/00 , A61P31/00 , A61P35/00
CPC分类号： C07D471/04
摘要： The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.
摘要翻译：本发明涉及具有萘啶支架的化合物，以及这些化合物的立体异构形式，前体药物，溶剂合物，水合物和/或药学上可接受的盐，以及含有这些萘啶衍生物中至少一种与药学上可接受的载体，赋形剂和 /或稀释剂。所述萘啶化合物已被鉴定为蛋白激酶ROCK2（也称为Rho-激酶）的抑制剂，可用于治疗癌症（肿瘤生长和转移），勃起功能障碍，心血管疾病，高血压，心绞痛，脑缺血，脑血管痉挛，心肌缺血，冠状动脉血管痉挛，心力衰竭，心肌肥大，动脉粥样硬化，再狭窄，脊髓损伤，神经元变性，血栓形成障碍，哮喘，青光眼，炎症，抗病毒疾病（例如HIV）和骨质疏松症。

2. 发明申请

WO2005023818A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS 审中-公开
标题翻译：作为药物活性剂的杂环化合物
公开(公告)号：WO2005023818A2
公开(公告)日：2005-03-17
申请号：PCT/EP2004/010161
申请日：2004-09-10
申请人： AXXIMA PHARMACEUTICALS AG , KOUL, Anil , KLEBL, Bert , MÜLLER, Gerhard , MISSIO, Andrea , SCHWAB, Wilfried , HAFENBRADL, Doris , NEUMANN, Lars , SOMMER, Marc-Nicola , MÜLLER, Stefan , HOPPE, Edmund , FREISLEBEN, Achim , BACKES, Alexander , HARTUNG, Christian , FELBER, Beatrice , ZECH, Birgit , ENGKVIST, Ola , KERI, György , ÖRFI, Laszlo , BANHEGYI, Peter , GREFF, Zoltan , HORVÁTH, Zoltán , VARGA, Zoltán , MARKO, Péter , PATÓ, Jànos , SZABADKAI, István , SZÉKELYHIDI, Zsolt , WÁCZEK, Frigyes
发明人： KOUL, Anil , KLEBL, Bert , MÜLLER, Gerhard , MISSIO, Andrea , SCHWAB, Wilfried , HAFENBRADL, Doris , NEUMANN, Lars , SOMMER, Marc-Nicola , MÜLLER, Stefan , HOPPE, Edmund , FREISLEBEN, Achim , BACKES, Alexander , HARTUNG, Christian , FELBER, Beatrice , ZECH, Birgit , ENGKVIST, Ola , KERI, György , ÖRFI, Laszlo , BANHEGYI, Peter , GREFF, Zoltan , HORVÁTH, Zoltán , VARGA, Zoltán , MARKO, Péter , PATÓ, Jànos , SZABADKAI, István , SZÉKELYHIDI, Zsolt , WÁCZEK, Frigyes
IPC分类号： C07D495/00
CPC分类号： C07D409/12 , C07D209/42 , C07D333/66 , C07D333/68 , C07D491/04 , C07D493/04 , C07D495/04 , C07D495/10
摘要： Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.
摘要翻译：描述了杂双环化合物，例如4,5,6,7-四氢＆shy;苯并[b]噻吩-3-羧酸酰胺，4,7-二氢-5H-噻吩并[2,3- C]噻喃＆害羞; 3-羧酸酰胺，4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-羧酸酰胺或苯并[b]噻吩-3-羧酸酰胺及其药学上可接受的盐，其用途这些衍生物用于预防和/或治疗各种疾病，如感染性疾病，包括分枝杆菌和害羞;诱导感染和机会性疾病，朊病毒疾病，免疫性疾病，自身免疫性疾病，双相性和临床疾病，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经退行性疾病和中风，以及含有至少一种杂双环化合物和/或其药学上可接受的盐的组合物。此外，公开了用于合成杂双环化合物的反应程序。

3. 发明申请

WO2006021458A2 PYRIMIDINE DERIVATIVES 审中-公开
标题翻译：吡嗪衍生物
公开(公告)号：WO2006021458A2
公开(公告)日：2006-03-02
申请号：PCT/EP2005/009291
申请日：2005-08-29
申请人： GPC BIOTECH AG , KLEBL, Bert , BAUMANN, Matthias , HOPPE, Edmund , BREHMER, Dirk , DAUB, Henrik , KÉRI, György , VARGA, Zoltán , MAROSFALVI, Jenö , ÖRFI, László
发明人： KLEBL, Bert , BAUMANN, Matthias , HOPPE, Edmund , BREHMER, Dirk , DAUB, Henrik , KÉRI, György , VARGA, Zoltán , MAROSFALVI, Jenö , ÖRFI, László
CPC分类号： C07D239/42 , C07D401/04 , C07D401/10 , C07D401/14
摘要： The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.
摘要翻译：本发明涉及嘧啶衍生物，其合成方法和所述嘧啶衍生物作为药物活性剂的用途，特别是用于预防和/或治疗细胞增殖障碍，癌症，白血病，勃起功能障碍，心血管疾病和病症，炎症性疾病，移植排斥反应，免疫疾病，神经免疫疾病，自身免疫疾病，感染性疾病，包括机会性感染，朊病毒疾病和/或神经变性。此外，本发明涉及含有至少一种嘧啶衍生物和/或其药学上可接受的盐作为活性成分以及至少一种药学上可接受的载体，赋形剂或稀释剂的药物组合物，以及用于预防和/或治疗上述疾病和障碍。

4. 发明申请

WO2006089874A1 BENZO[2,3]AZEPINO[4,5-B]INDOL-6-ONES 审中-公开
标题翻译：苯并[2,3]氮杂并[4,5-b]吲哚-6-酮
公开(公告)号：WO2006089874A1
公开(公告)日：2006-08-31
申请号：PCT/EP2006/060100
申请日：2006-02-20
申请人： GPC BIOTECH AG , KLEBL, Bert , NEUMANN, Lars , HAFENBRADL, Doris , GREFF, Zoltán , KÉRI, György , ÖRFI, László
发明人： KLEBL, Bert , NEUMANN, Lars , HAFENBRADL, Doris , GREFF, Zoltán , KÉRI, György , ÖRFI, László
IPC分类号： C07D487/04 , A61K31/55 , A61P25/00 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention relates to benzo[2,3]azepino[4,5-b]indol-6-ones of the general formula (I): and pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. Furthermore, the present invention is directed towards pharmaceutical composition containing at least one of the benzo[2,3]azepino[4,5-b]indol-6-ones and/or pharmaceutically acceptable salts thereof.
摘要翻译：本发明涉及通式（I）的苯并[2,3]氮杂环庚烯并[4,5-b]吲哚-6-酮及其药学上可接受的盐，这些化合物作为药物活性剂的用途，特别是传染病，包括机会性疾病，朊病毒疾病，免疫疾病，自身免疫疾病，双相和临床病症，心血管疾病，细胞增殖性疾病，糖尿病，炎症，移植排斥，勃起功能障碍，神经退行性疾病和中风的预防和/或治疗。此外，本发明涉及含有至少一种苯并[2,3]氮杂环庚烷并[4,5-b]吲哚-6-酮和/或其药学上可接受的盐的药物组合物。

5. 发明申请

WO2008132138A1 DERIVATIVES OF 4,6-DISUBSTITUTED AMINOPYRIMIDINES 审中-公开
标题翻译： 4,6-二取代氨基嘧啶的衍生物
公开(公告)号：WO2008132138A1
公开(公告)日：2008-11-06
申请号：PCT/EP2008/055015
申请日：2008-04-24
申请人： INGENIUM PHARMACEUTICALS GMBH , CHOIDAS, Axel , KLEBL, Bert , MÜLLER, Gerhard , SCHWAB, Wilfried
发明人： CHOIDAS, Axel , KLEBL, Bert , MÜLLER, Gerhard , SCHWAB, Wilfried
IPC分类号： C07D239/42 , A61K31/505 , A61P35/00
CPC分类号： C07D239/42
摘要： The present invention relates to methylenesulfone and methylenesulfonamide derivatives of 4,6-disubstituted aminopyrimidines having the general formula (II) as given below and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or the treatment of cell proliferative diseases, inflammation, cardiac hypertrophy and infectious diseases, especially viral infections such as HIV. Furthermore, the present invention is directed towards pharmaceutical composition containing at least one of the methylenesulfone or methylenesulfonamide derivatives of 4,6-disubstituted aminopyrimidines and/or pharmaceutically acceptable salts thereof.
摘要翻译：本发明涉及具有如下给出的通式（II）的4,6-二取代氨基嘧啶的亚甲基砜和亚甲基磺酰胺衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性物质特别是用于预防和/或治疗细胞增殖性疾病，炎症，心脏肥大和感染性疾病，特别是病毒感染如HIV。此外，本发明涉及含有至少一种4,6-二取代氨基嘧啶和/或其药学上可接受的盐的亚甲基砜或亚甲基磺酰胺衍生物的药物组合物。

6. 发明申请

WO2005105097A3 PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES 审中-公开
公开(公告)号：WO2005105097A3
公开(公告)日：2005-11-10
申请号：PCT/EP2005/051892
申请日：2005-04-27
申请人： GPC BIOTECH AG , DAUB, Henrik , WISSING, Josef , MISSIO, Andrea , KLEBL, Bert
发明人： DAUB, Henrik , WISSING, Josef , MISSIO, Andrea , KLEBL, Bert
IPC分类号： A61K31/513 , A61P29/00 , A61P37/00
摘要： The present invention relates to the use of pyridopyrimidine derivatives having the general formula (I) wherein X represents =NH, =N-Acyl, =O, or =S; R 1 represents -NR 3 R 4 , -SR 3 , -SO-R 3 , -SO 2 -R 3 , -OR 3 ; R 2 , R 3 , and R 4 are independently of each other hydrogen, -(CH 2 ) n Ph*, heteroaryl, C 3 -C 7 -cycloalkyl, C 1 -C 6 -alkyl, C 1 -C 6 -alkanoyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl; wherein the cycloalkyl, alkyl, alkanoyl, alkenyl, alkynyl residues can optionally substituted by one or more of the following groups: -NR 5 R 6 , phenyl, substituted phenyl, thioalkyl, alkyloxy, hydroxy, carboxy, halogen, cycloalkyl; R 5 and R 6 are independently of each other hydrogen, (CH 2 ) n Ph*, heteroaryl, C 3 -C 7 -cycloalkyl, C 1 -C 6 -alkyl, C 1 -C 6 -alkanoyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl; R 5 and R 6 can be taken together with the nitrogen to which they are attached to complete a ring having 3 to 7 carbon atoms, optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur; Ph* represents phenyl or substituted phenyl; n is 0, 1, 2, or 3; R 4 can optionally be -CO-R 3 , -CO-OR 3 , -SO 2 -R 3 , -SO 2 -NR 5 R 6 , -CO-NR 5 R 6 , -CS-NR 5 R 6 , -C(=NH)-R 3 , -C(=NH)-NR 5 R 6 ; R 3 and R 4 can be taken together with the nitrogen to which they are attached to complete a ring having 3 to 7 carbon atoms, optionally containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur; Ar represents phenyl, substituted phenyl, or heteroaryl; and pharmaceutically acceptable salts thereof for prophylaxis and/or treatment of inflammatory diseases, neurodegenerative disorders, immunological diseases, neuroimmunological diseases, autoimmune diseases, diabetes, transplant rejection, infective diseases, prion diseases, cardiovascular diseases and disorders.

7. 发明申请

WO2005120479A1 USE OF SELENIUM OR A SELENIUM SALT AND A RETINOID ACID OR A RETINOID IN THE TREATMENT OF VIRAL HEPATITIS C 审中-公开
标题翻译：在治疗病毒性肝炎的过程中使用硒或硒酸盐和杀真菌酸或抗真菌剂
公开(公告)号：WO2005120479A1
公开(公告)日：2005-12-22
申请号：PCT/EP2005/006226
申请日：2005-06-09
申请人： GPC BIOTECH AG , HERGET, Thomas , KLEBL, Bert
发明人： HERGET, Thomas , KLEBL, Bert
IPC分类号： A61K31/095
CPC分类号： A61K33/04 , A61K31/07 , A61K31/095 , A61K31/203 , A61K31/7056 , A61K38/21 , A61K2300/00
摘要： The present invention relates to combination therapies comprising at least one retinoid or retinoid agonist together with selenium or a selenium salt particularly useful in conjunction with conventional antiviral therapeutics which are synergistically effective against Hepatitis C virus (HCV) infections. In particular, the present invention relates to the synergism between compounds capable of activating or upregulating the gastrointestinal form of glutathione peroxidase for prophylaxis and/or treatment of HCV infections, administered in combination therapies with interferons. The combinations disclosed have proven surprisingly effective even in patients unresponsive to interferon/ribavirin therapies.
摘要翻译：本发明涉及包含至少一种类视黄醇或类视色素激动剂与硒或硒盐的组合疗法，其特别适用于与丙型肝炎病毒（HCV）感染协同有效的常规抗病毒治疗剂。特别地，本发明涉及能够激活或上调胃肠道形式的谷胱甘肽过氧化物酶用于预防和/或治疗HCV感染的化合物之间的协同作用，其与干扰素联合治疗。即使在对干扰素/利巴韦林治疗无反应的患者中，所公开的组合也已经被证明是惊人的。

8. 发明申请

WO2008129080A1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES 审中-公开
标题翻译：作为蛋白激酶抑制剂的4,6-取代的氨基嘧啶衍生物
公开(公告)号：WO2008129080A1
公开(公告)日：2008-10-30
申请号：PCT/EP2008/055017
申请日：2008-04-24
申请人： INGENIUM PHARMACEUTICALS GMBH , WABNITZ, Philipp , SCHAUERTE, Heike , ALLGEIER, Hans , AUGUSTIN, Martin , ZEITLMANN, Lutz , PLEISS, Michael A. , STUMM, Gabriele , MUELLER, Anke , CHOIDAS, Axel , KLEBL, Bert , MUELLER, Gerhard , SCHWAB, Wilfried , LE, Jolle , MACRITCHIE, Jackie , SIMPSON, Don
发明人： WABNITZ, Philipp , SCHAUERTE, Heike , ALLGEIER, Hans , AUGUSTIN, Martin , ZEITLMANN, Lutz , PLEISS, Michael A. , STUMM, Gabriele , MUELLER, Anke , CHOIDAS, Axel , KLEBL, Bert , MUELLER, Gerhard , SCHWAB, Wilfried , LE, Jolle , MACRITCHIE, Jackie , SIMPSON, Don
IPC分类号： C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/505 , A61P35/00
CPC分类号： C07D239/42 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要： The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
摘要翻译：本发明涉及细胞周期蛋白依赖性激酶的通式（I）的抑制剂及其治疗应用。此外，本发明涉及用于预防和/或治疗任何类型的疼痛，炎症性疾病，免疫疾病，增殖性疾病，感染性疾病，心血管疾病和神经变性疾病的化合物。

9. 发明申请

WO2013026890A1 SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS 审中-公开
标题翻译：选择性CDK9抑制剂的缺点
公开(公告)号：WO2013026890A1
公开(公告)日：2013-02-28
申请号：PCT/EP2012/066366
申请日：2012-08-22
申请人： LEAD DISCOVERY CENTER GMBH , MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. , CHOIDAS, Axel , KLEBL, Bert , HABENBERGER, Peter , EICKHOFF, Jan , THOMAS, Roman , HEUCKMANN, Johannes
发明人： CHOIDAS, Axel , KLEBL, Bert , HABENBERGER, Peter , EICKHOFF, Jan , THOMAS, Roman , HEUCKMANN, Johannes
IPC分类号： C12Q1/68
CPC分类号： G01N33/5011 , C12Q1/6881 , C12Q1/6886 , C12Q2600/106 , G01N2800/52
摘要： The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described. Furthermore, a kit useful for carrying out the methods described herein as well as an olieo- or polynucleotide canable of detecting rearrangements in the NUT nene are provided.
摘要翻译：本发明涉及选择（a）对选择性CDK9抑制剂具有敏感性的细胞，（a）组织或（a）细胞培养物的方法。本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用选择性CDK9抑制剂进行治疗的反应性的方法。特别地，本发明提供了用于鉴定对选择性CDK9抑制剂敏感的患者或患者的体外方法，由此患者怀疑患有NUT中线癌（NMC）。本发明还涉及监测或预测NUT中线癌（NMC）治疗功效的方法，其中特别设想用选择性CDK9抑制剂治疗。还描述了在NUT基因中具有至少一个重排的（转基因）非人动物或（转基因）细胞用于筛选和/或验证用于治疗NUT中线癌（NMC）的药物的用途。此外，提供了可用于实施本文所述方法的试剂盒以及可检测NUT烯内重排的醇或多核苷酸。

10. 发明申请

WO2012117059A1 PHARMACEUTICALLY ACTIVE DISUBSTITUTED PYRIDINE DERIVATIVES 审中-公开
标题翻译：药物活性分离的吡啶衍生物
公开(公告)号：WO2012117059A1
公开(公告)日：2012-09-07
申请号：PCT/EP2012/053517
申请日：2012-03-01
申请人： LEAD DISCOVERY CENTER GMBH , BAYER INTELLECTUAL PROPERTY GMBH , RÜHTER, Gerd , NUSSBAUMER, Peter , CHOIDAS, Axel , SCHULTZ-FADEMRECHT, Carsten , KLEBL, Bert , EICKHOFF, Jan
发明人： RÜHTER, Gerd , NUSSBAUMER, Peter , CHOIDAS, Axel , SCHULTZ-FADEMRECHT, Carsten , KLEBL, Bert , EICKHOFF, Jan
IPC分类号： C07D213/74 , A61K31/44 , A61P35/00
CPC分类号： C07D213/74 , A61K31/4418 , A61K45/06
摘要： The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.
摘要翻译：本发明涉及二取代的吡啶衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的用途，特别是用于预防和/或治疗感染性疾病，包括机会性疾病，免疫疾病，自身免疫性疾病，心血管疾病，细胞增殖性疾病，炎症，勃起功能障碍和中风，以及含有至少一种所述二取代吡啶衍生物和/或其药学上可接受的盐的药物组合物。此外，本发明涉及所述二取代的吡啶衍生物作为蛋白激酶的抑制剂的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式